Monoclonal antibody, gene encoding the antibody, hybridoma, pharmaceutical composition, and diagnostic reagent

A monoclonal antibody and composition technology, which can be used in drug combinations, anti-tumor drugs, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc., and can solve the problem of not developing antibodies.

Inactive Publication Date: 2009-03-18
MITSUBISHI TANABE PHARMA CORP +1
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no antibodies have been developed so far that can be used for directed therapy of cancers including non-small cell lung cancer or recalcitrant cancers such as pancreatic cancer, which afflicts many patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoclonal antibody, gene encoding the antibody, hybridoma, pharmaceutical composition, and diagnostic reagent
  • Monoclonal antibody, gene encoding the antibody, hybridoma, pharmaceutical composition, and diagnostic reagent
  • Monoclonal antibody, gene encoding the antibody, hybridoma, pharmaceutical composition, and diagnostic reagent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0074] Hereinafter, the present invention will be described in more detail with reference to Examples. However, the present invention is not limited to these examples without departing from the scope of the present invention.

[0075] (1) Preparation of hybridomas by cell fusion of lymphocytes obtained from local lymph node cancer of cancer patients and mouse myeloma

[0076] (1)-1: Preparation of lymphocytes

[0077] Carcinoma of regional lymph nodes resected from patients with gastric The isolated lymphocytes were dispersed on the metal mesh. Centrifuge the cell suspension at 3,000 rpm for 5 min to obtain approximately 4.8 × 10 7 A lymphocyte obtained from a carcinoma of a regional lymph node.

[0078] (1)-2: cell fusion

[0079] According to the standard method (Cancer Research (Cancer Research), Vol. 45, p. 263, 1985), the lymphocytes obtained from regional lymph node carcinoma and mouse myeloma cells (the number thereof) were separated with polyethylene glycol 1500 (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

Disclosed is a monoclonal antibody which has a heavy chain variable region containing amino acid sequences depicted in SEQ ID NOs:74, 76 and 78 and a light chain variable region containing amino acid sequences depicted in SEQ ID NOs:80, 82 and 84. The monoclonal antibody can be used as a cancer therapeutic agent which acts selectively on a cancer tissue of non-small lung cancer, pancreatic cancer, gastric cancer or the like.

Description

technical field [0001] The present invention relates to novel monoclonal antibodies useful for the diagnosis and treatment of cancer, DNA encoding the monoclonal antibodies, hybridomas producing the antibodies, pharmaceutical compositions and diagnostic reagents each containing the antibodies. Background technique [0002] In the field of cancer treatment, directed therapy against specific types of cancer cells has been currently being studied for the treatment of solid cancers, for which there are no therapeutic agents showing sufficient effects. In the targeted therapy, monoclonal antibodies that specifically recognize cancer cells are effective. However, the use of murine monoclonal antibodies has some problems, such as difficulty in repeated administration due to side effects such as allergic reactions caused by immune responses (Non-Patent Document 1). [0003] In order to overcome the problems, attempts have been made to obtain monoclonal antibodies with reduced side ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/00A61K9/127A61K39/395A61P35/00C07K16/30C12N1/15C12N1/19C12N1/21C12N5/10C12N15/09G01N33/577C12P21/08
CPCG01N33/57446G01N33/57423C07K2317/565G01N33/57438G01N33/57407A61K2039/505C07K2317/73C07K2317/56C07K16/30A61P35/00A61K39/395C12N15/00C12P21/00
Inventor 细川齐子平川容子福田和正中村理惠子才川义朗青木真彦熊井浩一郎
Owner MITSUBISHI TANABE PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap